ArticleJournal of cancer survivorship : research and practice2025
Re-examining survivorship research for people living with advanced and metastatic cancers: A portfolio analysis update of National Institutes of Health-funded grants.
Article in Journal of cancer survivorship : research and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe National Cancer Institute (NCI) identified survivorship research for people living with advanced and metastatic cancers as a priority in 2020. The goal of this portfolio analysis was to review all National Institutes of Health (NIH) grants newly funded in Fiscal Year (FY) 2021 to FY 2024 focused on this area.
methodsGrants were identified using a text mining algorithm of survivorship-relevant terms from the NIH Research, Condition, and Disease Categorization (RCDC) system and double coded for grant characteristics (e.g., study design, cancer type, primary focus, and primary outcomes).
resultsIncluded in this analysis were 63 grants, funded by 7 NIH institutes. The number of newly awarded grants funded rose from 9 in 2021 to 25 in 2024. The majority of grants were R01s (62.9%). Cancer types most often included were breast (22.2%), prostate (15.9%), and lung (15.9%). The primary focus of studies was most often acute toxicities (33.3%) or late- or long-term effects (33.3%). No grants focused on the financial impact of an advanced or metastatic cancer diagnosis.
conclusionsResults indicate a substantial growth in the number of grants funded from FY 2021 to FY 2024. Grants address some of the gap areas identified in previous NCI efforts, including longitudinal studies of symptoms. Scientific gap areas that persist include financial hardship and employment, models of care delivery, and prognostic uncertainty. IMPLICATIONS FOR CANCER SURVIVORS: Despite the growth in the grant portfolio, more research on survivors living with advanced and metastatic cancers is needed. This emerging population has unmet and understudied needs that will only expand given the growth in new therapies and targeted treatments.
Indexed as
Identifiers
41331232What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.